26.71
0.72 (2.77%)
| Previous Close | 25.99 |
| Open | 26.07 |
| Volume | 115,141 |
| Avg. Volume (3M) | 405,070 |
| Market Cap | 858,237,184 |
| Price / Earnings (TTM) | 14.36 |
| Price / Earnings (Forward) | 3.95 |
| Price / Sales | 1.73 |
| Price / Book | 3.79 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | 10.96% |
| Operating Margin (TTM) | 23.97% |
| Diluted EPS (TTM) | 1.86 |
| Quarterly Revenue Growth (YOY) | 21.50% |
| Quarterly Earnings Growth (YOY) | -60.80% |
| Total Debt/Equity (MRQ) | 428.20% |
| Current Ratio (MRQ) | 0.950 |
| Operating Cash Flow (TTM) | 204.98 M |
| Levered Free Cash Flow (TTM) | 362.08 M |
| Return on Assets (TTM) | 8.89% |
| Return on Equity (TTM) | 32.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Collegium Pharmaceutical, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.38 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.44% |
| % Held by Institutions | 118.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (HC Wainwright & Co., 87.20%) | Buy |
| Median | 48.00 (79.71%) | |
| Low | 46.00 (Needham, 72.22%) | Buy |
| Average | 48.00 (79.71%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 28.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 09 Apr 2025 | 46.00 (72.22%) | Buy | 26.37 |
| HC Wainwright & Co. | 24 Mar 2025 | 50.00 (87.20%) | Buy | 30.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Apr 2025 | Announcement | Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 |
| 01 Apr 2025 | Announcement | Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference |
| 27 Mar 2025 | Announcement | Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting |
| 17 Mar 2025 | Announcement | Collegium Announces Updates to its Board of Directors and Executive Leadership Team |
| 10 Mar 2025 | Announcement | Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care |
| 04 Mar 2025 | Announcement | Collegium to Participate in Upcoming Investor Conferences |
| 27 Feb 2025 | Announcement | Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results |
| 13 Feb 2025 | Announcement | Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |